National Agricultural Research Center for the Hokkaido Region, Sapporo, Hokkaido 062-8555, Japan.
J Biol Chem. 2011 Oct 7;286(40):34583-92. doi: 10.1074/jbc.M111.248138. Epub 2011 Aug 9.
The bifidogenic effect of human milk oligosaccharides (HMOs) has long been known, yet the precise mechanism underlying it remains unresolved. Recent studies show that some species/subspecies of Bifidobacterium are equipped with genetic and enzymatic sets dedicated to the utilization of HMOs, and consequently they can grow on HMOs; however, the ability to metabolize HMOs has not been directly linked to the actual metabolic behavior of the bacteria. In this report, we clarify the fate of each HMO during cultivation of infant gut-associated bifidobacteria. Bifidobacterium bifidum JCM1254, Bifidobacterium longum subsp. infantis JCM1222, Bifidobacterium longum subsp. longum JCM1217, and Bifidobacterium breve JCM1192 were selected for this purpose and were grown on HMO media containing a main neutral oligosaccharide fraction. The mono- and oligosaccharides in the spent media were labeled with 2-anthranilic acid, and their concentrations were determined at various incubation times using normal phase high performance liquid chromatography. The results reflect the metabolic abilities of the respective bifidobacteria. B. bifidum used secretory glycosidases to degrade HMOs, whereas B. longum subsp. infantis assimilated all HMOs by incorporating them in their intact forms. B. longum subsp. longum and B. breve consumed lacto-N-tetraose only. Interestingly, B. bifidum left degraded HMO metabolites outside of the cell even when the cells initiate vegetative growth, which indicates that the different species/subspecies can share the produced sugars. The predominance of type 1 chains in HMOs and the preferential use of type 1 HMO by infant gut-associated bifidobacteria suggest the coevolution of the bacteria with humans.
人乳寡糖(HMOs)的双歧因子作用早已为人所知,但其中的具体机制仍未得到解决。最近的研究表明,某些双歧杆菌物种/亚种拥有专门用于利用 HMOs 的基因和酶组,因此它们可以在 HMOs 上生长;然而,代谢 HMOs 的能力并未与细菌的实际代谢行为直接相关。在本报告中,我们阐明了在培养婴儿肠道相关双歧杆菌时每种 HMO 的命运。为此,选择了双歧杆菌 Bifidobacterium bifidum JCM1254、长双歧杆菌 Bifidobacterium longum subsp. infantis JCM1222、长双歧杆菌 Bifidobacterium longum subsp. longum JCM1217 和短双歧杆菌 Bifidobacterium breve JCM1192 用于该目的,并在含有主要中性寡糖部分的 HMO 培养基中进行培养。用 2- 邻氨基苯甲酸标记消耗培养基中的单糖和寡糖,并在不同孵育时间使用正相高效液相色谱法测定其浓度。结果反映了各自双歧杆菌的代谢能力。B. bifidum 使用分泌糖苷酶降解 HMOs,而 B. longum subsp. infantis 则通过完整地吸收所有 HMOs 进行同化。B. longum subsp. longum 和 B. breve 仅消耗乳糖-N-四糖。有趣的是,即使细胞开始进行营养生长,B. bifidum 也会将降解的 HMO 代谢产物留在细胞外,这表明不同的物种/亚种可以共享产生的糖。HMO 中类型 1 链的优势以及婴儿肠道相关双歧杆菌对类型 1 HMO 的优先利用表明了细菌与人类的共同进化。